Clinical trials: Metabolic-dysfunction Associated Steatotic Liver Disease
Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
Evaluating the Pharmacokinetics and Safety of Miricorilant
A Phase 1b, Open-Label Study Evaluating the Pharmacokinetics and Safety of Miricorilant in Adult Patients With Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Conditions
- Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis, Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-alcoholic Fatty Liver Disease (NAFLD)
- Trial name
- NCT07553663
- Testing
- Miricorilant
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Corcept Therapeutics
Obesity Type 2 Diabetes Mellitus, Cardiovascular-kidney-metabolic Syndrome
Early GLP-1 Receptor Agonist and SGLT2 Inhibitor Add-On Strategies in Adults With Obesity, Type 2 Diabetes, Cardiovascular-Kidney-Metabolic Syndrome Stage 2-3, and Metabolic Dysfunction-Associated Steatotic Liver Disease
This retrospective observational target-trial emulation uses electronic health record data from the TriNetX US Collaborative Network to compare early treatment intensification strategies in adults with obesity, type 2 diabetes…
- Conditions
- Obesity Type 2 Diabetes Mellitus, Cardiovascular-kidney-metabolic Syndrome, Metabolic Dysfunction-Associated Steatotic Liver Disease
- Trial name
- NCT07566299
- Volunteers
- 118,805 people
- Sponsor
- Chung Shan Medical University
Metabolic Dysfunction-Associated Steatotic Liver Disease Infant Development
TUDCA in High-Risk Lactating Mothers Identified by Early Postpartum Milk Hydrophobicity Index
This is a randomized, double-blind, placebo-controlled Phase 2 proof-of-concept trial in mother-infant dyads. The study aims to evaluate the safety, tolerability, and biological effects of maternal oral tauroursodeoxycholic acid…
- Trial name
- MILK-HI-TUDCA (NCT07517276)
- Testing
- tauroursodeoxycholic acid (TUDCA)
- Volunteers
- 80 people
- Sponsor
- Peking University First Hospital
Metabolic Dysfunction-Associated Steatotic Liver Disease, Overweight
Study of Grape Consumption in Adaptation to Seasonal Photoperiod
The goal of this randomized clinical trial is to learn whether consuming grapes during their natural season can help the body adapt to the shorter daylight hours of winter.
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Overweight, Obesity & Overweight
- Trial name
- PhotoGrape (NCT07886788)
- Testing
- Freeze-Dried Grape Powder, Plain Low-Fat Yogurt, Mediterranean-Style Dietary Guidance
- Where
- Spain
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- University Rovira i Virgili
Nonalcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease (NAFLD)
The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
The goal of this clinical trial is to learn if daily supplementation with Low-methoxy (LM) pectin (polysaccharides extracted from citrus peels), which are commonly found in the UK diet (not pharmacological agents), can reduce…
- Conditions
- Nonalcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease (NAFLD), MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
- Trial name
- PEC-MASLD (NCT07093346)
- Testing
- Pectin, Cocoa Powder, Magnetic Resonance Imaging with Contrast
- Where
- 3 sites in United Kingdom
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University of Nottingham
Metabolic Dysfunction Associated Steatotic Liver Disease, Compensated Cirrhosis
Prognostic Model for MASLD Related Cirrhosis
This study enrolled 228 patients with MASLD-related cirrhosis confirmed by histopathology or clinical diagnosis. Follow-up was conducted every 3-6 months.
- Trial name
- NCT07082751
- Testing
- Lifestyle Guidance
- Where
- 9 sites in China
- Volunteers
- 228 people
- Sponsor
- Beijing Friendship Hospital
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
Integrating Hepatological, Nutritional, and Psychological Support as a Multidisciplinary Management to Improve Long-term Clinical Outcomes in MASLD
Metabolic dysfunction associated Steatotic Liver Disease (MASLD) is frequently complicated by cardiometabolic (CMR) comorbidities, and prognosis is substantially influenced by acute cardiovascular events (ACE).
- Conditions
- MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD, Cardiovascular Events
- Trial name
- CoCoNut (NCT07366463)
- Testing
- Hepatologic-provided recommendations, Nutritional support, Psychological support
- Where
- Italy
- Volunteers
- 286 people
- Sponsor
- University of Campania Luigi Vanvitelli
MASLD, MASH
A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH
A phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and tolerability of denifanstat 50 mg compared to placebo in patients with metabolic dysfunction-associated steatotic liver disease…
- Conditions
- MASLD, MASH, NASH, Metabolic Dysfunction-Associated Steatotic Liver Disease
- Trial name
- FASCINIT (NCT06692283)
- Testing
- denifanstat
- Sponsor
- Sagimet Biosciences Inc.
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Liver Fibrosis/NASH
Stimulating Fat Tissue Storage With Niacin to Reduce Fat Accumulation in the Liver.
Metabolic dysfunction-associated steatotic liver disease (MASLD) (aka non-alcoholic fatty liver disease), commonly occurring in individuals with obesity and type 2 diabetes can lead to liver inflammation/ fibrosis.
- Conditions
- Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Liver Fibrosis/NASH, Non-Alcoholic Steato-Hepatitis (NASH)
- Trial name
- AGL13 (NCT06843148)
- Testing
- Niacin (250mg)
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- Université de Sherbrooke
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
MASLD Butyrate Supplementation Treatment Efficacy Review
1. Study Design This is an interventional study designed to evaluate the efficacy of oral butyrate supplementation in patients diagnosed with metabolic dysfunction-associated steatotic liver disease (MASLD). 2.
- Trial name
- MASTER (NCT06759363)
- Testing
- Sodium-Butyrate, Calcium Butyrate
- Where
- Serbia
- Volunteers
- 200 people
- Sponsor
- University Medical Center Zvezdara
Metabolic Dysfunction-Associated Steatotic Liver Disease
Clinical Profile of Patients With MASLD in Kazakhstan and Clinical Effectiveness of Ursosan in Almaty
This study will look at the health characteristics of adults with metabolic dysfunction-associated steatotic liver disease (MASLD) in Kazakhstan.
- Trial name
- NCT07889999
- Where
- 7 sites in Kazakhstan
- Volunteers
- 420 people
- Sponsor
- Kazakh Association of Internal Medicine Specialists
Fatty Liver, Nonalcoholic
The Impact Of SGLT2 -I on Metabolic Dysfunction -Associated Steatotic Liver Disease In Patients With Type 2 Diabetes Mellitus
Study question 1:Could SGLT2-I improve hepatic fibrosis, steatosis, and inflammatory markers in type 2 diabetic patients with Metabolic associated steatotic liver disease Question 2:Which drug of SGLT2-I group is more effective…
- Trial name
- NCT06117137
- Testing
- SGLT2 inhibitor
- Where
- Egypt
- Volunteers
- 150 people
- Sponsor
- Sohag University
NASH/MASH, NAFLD/MASLD
A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
The aim of this study is to assess the safety and tolerability of EFX compared to placebo in subjects with non-invasively diagnosed NASH/MASH and NAFLD/MASLD.
- Trial name
- NCT06161571
- Testing
- Efruxifermin
- Where
- 211 sites in United States, Argentina and 11 more
- Volunteers
- 700 people
- Sponsor
- Akero Therapeutics, Inc
Metabolic Dysfunction-Associated Steatoic Liver Disease
A Phase 2a Study of Kylo-0603 Capsule in Participants With Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD)
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a metabolic stress-related liver injury closely associated with insulin resistance, with a global prevalence of approximately 25%.
- Trial name
- NCT07878091
- Testing
- Kylo 0603 Capsule 8mg, Kylo 0603 Capsule 12mg, Kylo 0603 Capsule 16mg
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Breast Cancer Survivors, Colorectal (Colon or Rectal) Cancer Survivors
The Development of MASLD Among Survivors of Breast or Colorectal Cancer
A metabolic issue is a condition where the body has problems with converting food into energy, using energy or storing energy properly.
- Conditions
- Breast Cancer Survivors, Colorectal (Colon or Rectal) Cancer Survivors, MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
- Trial name
- EVALUATE (NCT07280143)
- Where
- Switzerland
- Volunteers
- 200 people
- Sponsor
- University of Bern
Metabolic Dysfunction Associated Steatotic Liver Disease
Aspirin for Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of chronic liver disease worldwide and a significant public health issue. MASLD may progress to liver cirrhosis and/or hepatocellular carcinoma.
- Trial name
- NCT06935994
- Testing
- Aspirin 81 mg Enteric Coated Tab - 1 tablet
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- Taichung Veterans General Hospital
Metabolic Dysfunction-Associated Steatotic Liver Disease
Ultrasound Liver Imaging for Classification of Metabolic Dysfunction-associated Steatotic Liver Disease
Tissue elasticity and viscosity correlate with pathology. These tissue properties are typically evaluated subjectively using palpation.
- Trial name
- NCT07373769
- Testing
- Ultrasound and magentic resonance imaging
- Where
- Canada
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Fatty Liver, Nonalcoholic
Probiotic Supplement Versus Placebo for the Treatment of Patients With Non-alcoholic Fatty Liver Disease
Probiotic supplement versus placebo for the treatment of patients with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial
- Trial name
- NCT06491342
- Testing
- Probiotic
- Where
- 2 sites in Thailand
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Phramongkutklao College of Medicine and Hospital
Metabolic Dysfunction-Associated Steatotic Liver Disease, Liver Fibrosis
Automated Passive Case-Finding for Advanced Liver Fibrosis in MASLD: The LiverSeek Programme
LiverSeek is a fully automated, passive case-finding programme for advanced liver fibrosis associated with metabolic dysfunction-associated steatotic liver disease (MASLD) in primary care.
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Liver Fibrosis, Non-alcoholic Fatty Liver Disease NAFLD, Type 2 Diabetes Mellitus
- Trial name
- LiverSeek (NCT07658755)
- Where
- Spain
- Volunteers
- 3,000 people
- Sponsor
- Hospital General Universitario Gregorio Marañon
MASLD, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Chrononutrition/ Chronotoxicity Intervention in People With Metabolic-associated Steatotic Liver Disease.
The goal of this clinical trial is to study the effect of a time-restricted eating (TRE) dietary pattern combined with a time of consumption restriction about the daily portions of fruits and vegetables in people diagnosed with…
- Conditions
- MASLD, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, NAFLD, NAFLD - Non-Alcoholic Fatty Liver Disease
- Trial name
- CHRONOMASLD (NCT06705868)
- Testing
- Diet-Time-restricted eating (TRE), Lifestyle Management
- Where
- Cyprus
- Volunteers
- 150 people
- Sponsor
- Cyprus University of Technology